Skip to content
LearnGet started
All articles

News

Lilly sues five more sellers over unapproved retatrutide

·3 min read ·By Chris Burkett

Listen to this article
Lilly sues five more sellers over unapproved retatrutide
Eli Lilly and Company Corporate Center in Indianapolis. Photo: Momoneymoproblemz via Wikimedia Commons, CC BY-SA 4.0.

Eli Lilly is going to court again over a weight loss drug that is not approved anywhere in the world. On October 8 the company filed five new lawsuits against businesses it says are selling retatrutide, its experimental obesity medicine, directly to consumers.

Who was sued

According to Buchanan Ingersoll & Rooney’s summary of the filings, the October defendants are three online retailers, American Peptides LLC, Cenexa Labs LLC and LiveWell Peptides, plus a weight loss clinic, MedShape Weight Loss Clinic, and a med spa, Southlake Mhya PLLC, doing business as Medrein Health & Aesthetics.

Lilly alleges the online sellers use “research use only” labels to disguise products meant for people to inject. It brings claims under the federal Lanham Act and state consumer protection and unfair competition laws, and is seeking injunctions, money damages and legal fees.

The suits follow six others Lilly filed in August against med spas, a compounding pharmacy and online sellers in California and Texas.

What retatrutide is, and is not

Retatrutide is an investigational drug that acts on three hormone receptors involved in appetite and metabolism. It is still in Phase 3 clinical trials. Lilly says no retatrutide medicine has been approved for human use by any regulator.

That means anything sold as retatrutide today did not come from Lilly, has not been reviewed for safety or purity, and has no approved dose. The FDA has warned consumers not to buy these products, which it describes as being of unknown quality and possibly harmful.

In August Lilly also said it had referred more than 200 people and businesses to regulators and law enforcement, and reported more than 14,000 websites, ads, social media posts and product listings.

Why “research use only” is a red flag

The research-peptide market has grown alongside demand for GLP-1 medicines. Sellers often post the words “not for human consumption” next to dosing charts and injection guides. Connecticut’s attorney general has also acted this year against an online platform and a med spa over bootleg and unapproved weight loss drugs.

What to look for instead

Any legitimate weight loss treatment, from an approved brand or a state-licensed pharmacy, starts with a licensed clinician reviewing your health history and writing a prescription. The medication is dispensed by a licensed pharmacy and comes with instructions from your care team.

If a website offers you an unapproved drug with no prescription, no clinician and a “research” disclaimer, it is not a shortcut. Walk away.

Photo: Eli Lilly and Company Corporate Center in Indianapolis. Momoneymoproblemz via Wikimedia Commons, CC BY-SA 4.0.

Sources


See what a Living+ plan costs and whether it fits.

See treatments and pricing

Tags telehealth
This article is general education from Living+, not medical advice or a substitute for care from your provider. Treatment decisions are made by a licensed provider based on your individual health history.
Share

Start with a conversation.

Share your history. A licensed provider decides whether care through Living+ is right for you. Nothing is charged unless they prescribe a plan.

See if you qualify
Licensed providers in all 50 states and Washington, D.C.